EWGFF yields 5714.29% · PFE yields 6.13%● Live data
📍 EWGFF pulled ahead of the other in Year 1
Combined, EWGFF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EWGFF + PFE for your $10,000?
Eat Well Investment Group Inc. is a venture capital firm specializing in early-stage, seed and emerging growth investments. The firm seeks to invest at various stages of development, including pre-initial public offering, and/or early stage companies requiring start-up or development capital. The firm seeks to invest in agribusiness, food-tech, consumer packaged goods (CPG), plant-based and ESG (environmental, social and governance) sectors. The firm also seeks to invest in marketable securities comprising common shares and other equity instruments of companies in the mining, oil and gas, media technology, and medical technology industries that are listed on various Canadian stock exchanges or the OTCBB in the United States. It considers to invest over a number of sectors, including but not limited to: precision fermentation, regenerative agriculture, fintech, healthcare, the resource sector, information and communications technology, and energy & clean technology. It typically invests in Canada and the United States. The firm seeks to invest between $0.25 million to $2 million. The firm is also involved in assisting financing, identifying acquisition targets, developing strategic plans, supporting operations, and implementing exit strategies. The firm also works with co-investors. Eat Well Investment Group Inc. was founded in 2007 and is based in Vancouver, Canada.
Full EWGFF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.